Browsing: Lilly

Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The company focuses on mental health treatments using psychedelic-based compounds. AtaiBeckley is developing an intranasal formulation for treatment-resistant depression. Talks are ongoing, and a deal could be announced this week

Eli Lilly is the leader in the weight loss drug market — a market on track to reach almost $100 billion

Eli Lilly & Co. (LLY)’s reign atop the red-hot GLP-1 weight-loss drug market is getting fresh validation from surging U.S. consumer adoption, as new polling shows usage nearly tripling in two years. With the drugmaker’s market value now topping $1 trillion and its stock up more than 400% over half a decade, investors are weighing…

Eli Lilly’s shareholders are in store for even more gains, according to a respected investment bank

Obesity drugs might be the hottest growth story in healthcare right now. GLP-1 agonists and similar drugs encourage weight loss for managing obesity and treating type 2 diabetes. The viral success of Mounjaro and Zepbound has made Eli Lilly (NYSE: LLY) a home run winner. The stock’s 160% run over the past three years has…

Eli Lilly and Company (LLY) is up 3.2% today. Here is some analysis on what might have caused this price movement

Zepbound from Eli Lilly & Co. sits in a pharmacist’s refrigerator behind a glass door, its slim injection pens lined up like muted blue markers ready for Sunday night routines. In New York, an endocrinologist told me patients now set calendar alerts for their weekly dose. The vibe is practical, not glamorous, but the weight-loss…